Full Text
PT44 Cost-Effectiveness of Olaparib Vs. Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer – the Canadian Perspective

Abstract

Authors

I. Yanev A. Aprikian B.L. Raizenne A. Dragomir

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×